BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, June 7, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 14, 2015
View Archived Issues
FDA grants QIDP status to WCK-5222
Read More
Vitae Pharmaceuticals begins phase IIa trial of VTP-38543 in atopic dermatitis
Read More
First subject dosed in phase I trial of TD-1473
Read More
COTI-2 advances into human testing
Read More
NORD receives FDA grant to study natural history of rare diseases
Read More
Preclinical efficacy of first-in-class TCB antibody EM-801
Read More
DMC recommends continuation of phase III trial of AGS-003 in RCC following second interim analysis
Read More
Janssen starts first-in-human trial of Aduro's ADU-214 in patients with NSCLC
Read More
Anti-HLA-DR antibody IMMU-114 demonstrates activity in first-in-human study
Read More
Burixafor/G-CSF promote impressive hematopoietic stem cell mobilization in MM, NHL and HL patients
Read More
Interim phase II data for isatuximab in refractory/relapsed multiple myeloma
Read More
Ularitide receives FDA fast track designation for acute decompensated heart failure
Read More
Agreements signed by Bristol-Myers Squibb, Kyorin, Novartis, Rhizen, AGTC and Synpromics
Read More
Ninlaro now available in the U.S.
Read More
Synergy seen with CDK9 inhibitors and venetoclax in lymphoma cells
Read More
ACE-083 increases muscle volume in phase I study
Read More
FDA approves Vistogard to treat overdose or severe toxicities due to 5-FU or capecitabine
Read More
GlaxoSmithKline patents ROR-gamma modulators
Read More
Mitsubishi Tanabe Pharma discloses MC1 receptor agonists
Read More
Novartis reports MALT1 inhibitors
Read More
Medshine Discovery introduces anti-HBV compounds
Read More
Pfizer discloses Nav1.7 channel blockers
Read More
Merck & Co. patents GPR40 agonists
Read More
Preclinical and clinical data reported for multiple myeloma candidate ACY-241
Read More
Chimeric antigen receptor-modified T cells induce partial remission in first AML patient treated
Read More
FDA grants accelerated approval to Alecensa
Read More
FDA approves Otiprio for pediatric patients undergoing tympanostomy tube placement
Read More
